SCHEMBL5887287

SCHEMBL5887287

COC1=CC[CH]C(c2ccc(OC)cc2)=C1c1ccc(C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.46
NPC1 O15118 5/20 0.41
RAB9A P51151 5/20 0.41
KMT2A Q03164 2/20 0.41
ALOX5 P09917 2/20 0.39
RELA Q04206 1/20 0.39
ALKBH3 Q96Q83 2/20 0.38
MEN1 O00255 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
MAPT P10636 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 1/20 0.37
GAA P10253 1/20 0.37
ME2 P23368 1/20 0.36
ME1 P48163 1/20 0.36
ME3 Q16798 1/20 0.36
EGFR P00533 1/20 0.35
KDR P35968 1/20 0.35
HPGD P15428 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887143 0.87 PTGS2 (0.35) RAB9AKMT2AALKBH3MEN1NPSR1
SCHEMBL5887073 0.86 ACHE (0.47) ACHENPC1RAB9AKMT2AALOX5
SCHEMBL5887433 0.84 ACHE (0.44) ACHENPC1RAB9AKMT2AALOX5
SCHEMBL5887353 0.81 MEN1 (0.35) ACHENPC1RAB9AKMT2AALKBH3
SCHEMBL6047593 0.80 ALKBH3 (0.36) ALKBH3EGFRHPGD
SCHEMBL6416879 0.80 HPGD (0.32) KMT2AALOX5MEN1HPGD
SCHEMBL5887347 0.78 MEN1 (0.35) KMT2AMEN1MAPT
SCHEMBL5887105 0.78 ESR2 (0.35) NPC1ALOX5SMN1; SMN2MAPT
SCHEMBL6047646 0.77 CYP2D6 (0.32) ALKBH3HPGD
SCHEMBL5887217 0.77 ACHE (0.47) ACHENPC1RAB9AKMT2AALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US claimed
JP-2006501194-A 2006-01-12 JP claimed
EP-1525190-A1 CCK-1 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2005-04-27 EP claimed
WO-2004007463-A1 CCK-1 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2004-01-22 WO claimed
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R ACHE 915/4885NPC1 1831/4885RAB9A 1054/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R ACHE 3650/4885NPC1 2930/4885RAB9A 1724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.